Pathophysiology of systemic sclerosis: State of the art in 2014

Presse Medicale

Volumn 43, Issue 10, 2014, Pages e267-e278

  Dumoitier, Nicolas ^a,b   Lofek, Sébastien ^a   Mouthon, Luc ^a,c  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Université Paris Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INTERFERON; INTERFERON REGULATORY FACTOR 5; MAJOR HISTOCOMPATIBILITY ANTIGEN; OX40 LIGAND; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STAT4 PROTEIN;

B LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CHICKEN MODEL; CYTOKINE RESPONSE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FIBROBLAST; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; HEREDITY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE MODEL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SHORT SURVEY; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; ANIMAL; DISEASE MODEL; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; IMMUNE SYSTEM; SCLERODERMA, SYSTEMIC;

EID: 84908463840     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.08.001     Document Type: Short Survey

References (125)

1. Tamby M.C., Chanseaud Y., Guillevin L., Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003, 2:152-157.
2. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
3. Le Guern V., Mahr A., Mouthon L., Jeanneret D., Carzon M., Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004, 43:1129-1137.
4. Mouthon L., Allanore Y., Cabane J., Hachulla E. Sclérodermve systémique. Maladies et syndromes systémiques 2008, 410-470. Flammarion Médecine-Sciences, Paris.
5. Nietert P.J., Silver R.M. Systemic sclerosis: environmental and occupational risk factors. Curr Opin Rheumatol 2005, 12:520-526.
6. Janowsky E.C., Kupper L.L., Hulka B.S. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 2000, 342:781-790.
7. Englert H., Small-McMahon J., Davis K., O'Connor H., Chambers P., Brooks P. Male systemic sclerosis and occupational silica exposure-a population-based study. Aust N Z J Med 2000, 30:215-220.
8. Diot E., Lesire V., Guilmot J.L., Metzger M.D., Pilore R., Rogier S., et al. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med 2002, 59:545-549.
9. Nietert P.J., Sutherland S.E., Silver R.M., Pandey J.P., Knapp R.G., Hoel D.G., et al. Is occupational organic solvent exposure a risk factor for scleroderma?. Arthritis Rheum 1998, 41:1111-1118.
10. Marie I., Gehanno J.F., Bubenheim M., Duval-Modeste A.B., Joly P., Dominique S., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13:151-156.
11. Varga J., Schumacher H.R., Jimenez S.A. Systemic sclerosis after augmentation mammoplasty with silicone implants. Ann Intern Med 1989, 111:377-383.
12. Garabrant D.H., Lacey J.V., Laing T.J., Gillespie B.W., Mayes M.D., Cooper B.C., et al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003, 157:493-500.
13. Lunardi C., Bason C., Navone R., Millo E., Damonte G., Corrocher R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000, 6:1183-1186.
14. Halenius A., Hengel H. Human cytomegalovirus autoimmune disease. Biomed Res Int 2014, 2014:472978.
15. Arnett F.C., Cho M., Chatterjee S., Aguilar M.B., Reveille J.D., Mayes M.D. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001, 44:1359-1362.
16. Feghali-Bostwick C., Medsger T.A., Wright T.M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956-1963.
17. Allanore Y., Wipff J., Kahan A., Boileau C. Genetic basis for systemic sclerosis. Joint Bone Spine 2007, 74:577-583.
18. Wipff J., Giraud M., Sibilia J., Mouthon L., Meyer O., Tiev K., et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 2008, 35:643-649.
19. Manetti M., Allanore Y., Revillod L., Fatini C., Guiducci S., Cuomo G., et al. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum 2011, 63:247-256.
20. Manetti M., Rosa I., Milia A.F., Guiducci S., Carmeliet P., Ibba-Manneschi L., et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?. Ann Rheum Dis 2014, 73:1700-1709.
21. Bossini-Castillo L., Simeon C.P., Beretta L., Broen J., Vonk M.C., Callejas J.L., et al. KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. Arthritis Res Ther 2012, 14:R273.
22. Manku H., Langefeld C.D., Guerra S.G., Malik T.H., Alarcon-Riquelme M., Anaya J.M., et al. Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet 2013, 9:e1003554.
23. Gourh P., Arnett F.C., Tan F.K., Assassi S., Divecha D., Paz G., et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010, 69:550-555.
24. Bossini-Castillo L., Broen J.C.A., Simeon C.P., Beretta L., Vonk M.C., Ortego-Centeno N., et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 2011, 70:638-641.
25. Coustet B., Bouaziz M., Dieudé P., Guedj M., Bossini-Castillo L., Agarwal S., et al. Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J Rheumatol 2012, 39:997-1003.
26. Ito I., Kawaguchi Y., Kawasaki A., Hasegawa M., Ohashi J., Hikami K., et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009, 60:1845-1850.
27. Dieudé P., Guedj M., Wipff J., Avouac J., Fajardy I., Diot E., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009, 60:225-233.
28. Sharif R., Mayes M.D., Tan F.K., Gorlova O.Y., Hummers L.K., Shah A.A., et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis 2012, 71:1197-1202.
29. Lindahl G.E., Stock C.J., Shi-Wen X., Leoni P., Sestini P., Howat S.L., et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res 2013, 14:80.
30. Watford W.T., Hissong B.D., Bream J.H., Kanno Y., Muul L., O'Shea J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004, 202:139-156.
31. Avouac J., Fürnrohr B.G., Tomcik M., Palumbo K., Zerr P., Horn A., et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011, 63:800-809.
32. Gourh P., Tan F.K., Assassi S., Ahn C.W., McNearney T.A., Fischbach M., et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006, 54:3945-3953.
33. Diaz-Gallo L.M., Gourh P., Broen J., Simeon C., Fonollosa V., Ortego-Centeno, et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011, 70:454-462.
34. Martin J.E., Broen J.C., Carmona F.D., Teruel M., Simeon C.P., Vonk M.C., et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet 2012, 21:2825-2835.
35. Radstake T.R.D.J., Gorlova O., Rueda B., Martin J.E., Alizadeh B.Z., Palomino-Morales R., et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010, 42:426-429.
36. Dieudé P., Boileau C., Guedj M., Avouac J., Ruiz B., Hachulla E., et al. Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Ann Rheum Dis 2011, 70:1695-1696.
37. Rueda B., Gourh P., Broen J., Agarwal S.K., Simeon C., Ortego-Centeno N., et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 2010, 69:700-705.
38. Dieudé P., Wipff J., Guedj M., Ruiz B., Melchers I., Hachulla E., et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009, 60:3447-3454.
39. Ito I., Kawaguchi Y., Kawasaki A., Hasegawa M., Ohashi J., Kawamoto M., et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010, 62:890-895.
40. Coustet B., Dieudé P., Guedj M., Bouaziz M., Avouac J., Ruiz B., et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. Arthritis Rheum 2011, 63:2091-2096.
41. Dieudé P., Guedj M., Wipff J., Ruiz B., Riemekasten G., Matucci-Cerinic M., et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 2010, 69:1958-1964.
42. Arnett F.C., Gourh P., Shete S., Ahn C.W., Honey R.E., Agarwal S.K., et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010, 69:822-827.
43. Allanore Y., Saad M., Dieudé P., Avouac J., Distler J.H.W., Amouyel P., et al. Genome-wide scan identifies TNIP1 PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011, 7:e1002091.
44. Gorlova O., Martin J.E., Rueda B., Koeleman B.P.C., Ying J., Teruel M., et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011, 7:e1002178.
45. Gilchrist F.C., Bunn C., Foley P.J., Lympany P.A., Black C.M., Welsh K.I. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001, 2:76-81.
46. Chatterjee S., Mark M.E., Wooley P.H., Lawrence W.D., Mayes M.D. Increased dermal elastic fibers in the tight skin mouse. Clin. Exp. Rheumatol 2004, 22:617-620.
47. Krieg T., Abraham D., Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007, 9:S4.
48. Delany A.M., Brinckerhoff C.E. The synthetic retinoid (4-hydroxyphenyl) retinamide decreases collagen expression in vitro and in the tight-skin mouse. Arthritis Rheum 1993, 36:983-993.
49. Jimenez S.A., Williams C.J., Myers J.C., Bashey R.I. Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem 1986, 261:657-662.
50. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
51. Cottin V., Nunes H., Mouthon L., Gamondes D., Lazor R., Hachulla E., et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011, 63:295-304.
52. Christner P.J., Peters J., Hawkins D., Siracusa L.D., Jiménez S.A. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 1995, 38:1791-1798.
53. Artlett C.M. Animal models of scleroderma: fresh insights. Curr Opin Rheumatol 2010, 22:677-682.
54. Rose N.R. Avian models of autoimmune disease: lessons from the birds. Poult Sci 1994, 73:984-990.
55. Wick G., Andersson L., Hala K., Gershwin M.E., Selmi C., Erf G.F., et al. Avian models with spontaneous autoimmune diseases. Adv Immunol 2006, 92:71-117.
56. Derrett-Smith E.C., Denton C.P., Sonnylal S. Animal models of scleroderma: lessons from transgenic and knockout mice. Curr Opin Rheumatol 2009, 21:630-635.
57. Sonnylal S., Denton C.P., Zheng B., Keene D.R., He R., Adams H.P., et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007, 56:334-344.
58. Ben-David Y., Giddens E.B., Bernstein A. Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus. Proc Natl Acad Sci USA 1990, 87:1332-1336.
59. Kubo M., Czuwara-Ladykowska J., Moussa O., Markiewicz M., Smith E., Silver R.M., et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003, 163:571-581.
60. Wang Y., Fan P.S., Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54:2271-2279.
61. Asano Y., Sato S. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 2013, 15:382.
62. Servettaz A., Goulvestre C., Kavian N., Nicco C., Guilpain P., Chéreau C., et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009, 182:5855-5864.
63. Sambo P., Baroni S.S., Luchetti M., Paroncini P., Dusi S., Orlandini G., et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001, 44:2653-2664.
64. Kavian N., Marut W., Servettaz A., Nicco C., Chéreau C., Lemaréchal H., et al. Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis. Arthritis Rheum 2012, 64:3430-3440.
65. Mountz J.D., Downs Minor M.B., Turner R., Thomas M.B., Richards F., Pisko E. Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983, 108:679-686.
66. Zhang Y., Gilliam A.C. Animal models for scleroderma: an update. Curr Rheumatol Rep 2002, 4:150-162.
67. Ishikawa H., Takeda K., Okamoto A., Matsuo S., Isobe K. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol 2009, 129:1688-1695.
68. Iwamoto N., Distler J.H.W., Distler O. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr Rheumatol Rep 2011, 13:21-27.
69. Herrick A.L., Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001, 19:4-8.
70. Fubini B., Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003, 34:1507-1516.
71. Allanore Y., Borderie D., Lemaréchal H., Ekindjian O.G., Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004, 116:595-600.
72. Solans R., Motta C., Solá R., La Ville A.E., Lima J., Simeón P., et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 2000, 43:894-900.
73. Sambo P., Jannino L., Candela M., Salvi A., Donini M., Dusi S. Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999, 112:78-84.
74. Servettaz A., Guilpain P., Goulvestre C., Chéreau C., Hercend C., Nicco C., et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007, 66:1202-1209.
75. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005, 280:36474-36482.
76. Avouac J., Borderie D., Ekindjian O.G., Kahan A., Allanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol 2010, 37:2540-2547.
77. Rosen A., Casciola-Rosen L., Wigley F. Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 1997, 9:538-543.
78. Bhattacharyya S., Wei J., Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012, 8:42-54.
79. Kahaleh M.B., Osborn I., LeRoy E.C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981, 94:482-484.
80. Bordron A., Dueymes M., Levy Y., Jamin C., Leroy J.P., Piette J.C., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998, 101:2029-2035.
81. Liberati A.P.T., Ribeiro C.F., Skare T. Study about the association between anticardiolipin antibodies and peripheral vascular phenomena in patients suffering from systemic scleroderma. An Bras Dermatol 2010, 85:403-405.
82. Kahaleh M.B. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991, 34:978-983.
83. Marsault R., Vigne P., Frelin C. High reactivity of aortic fibroblasts to vasoactive agents: endothelins, bradykinin and nucleotides. Biochem Biophys Res Commun 1992, 188:205-208.
84. Mouthon L., Mehrenberger M., Teixeira L., Fakhouri F., Bérezné A., Guillevin L., et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011, 42:95-102.
85. Kovacs G., Maier R., Aberer E., Brodmann M., Graninger W., Kqiku X., et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012, 64:1257-1262.
86. Schachna L., Wigley F.M. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 2002, 14:686-693.
87. Distler O., Distler J.H.W., Scheid A., Acker T., Hirth A., Rethage J., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95:109-116.
88. Denton C.P., Shi-Wen X., Sutton A., Abraham D.J., Black C.M., Pearson J.D. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998, 114:293-300.
89. Krieg T., Abraham D., Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007, 9(Suppl 2):S4.
90. Santiago B., Galindo M., Rivero M., Pablos J.L. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001, 44:1667-1676.
91. Van der Slot A.J., Zuurmond A.M., Bardoel A.F.J., Wijmenga C., Pruijs H.E.H., Sillence, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 2003, 278:40967-40972.
92. Smith E.A., LeRoy E.C. A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990, 95:125S-127S.
93. Kawakami T., Ihn H., Xu W., Smith E., LeRoy C., Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998, 110:47-51.
94. Chen S.J., Yuan W., Mori Y., Levenson A., Trojanowska M., Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 1999, 112:49-57.
95. Bhattacharyya S., Ghosh A.K., Pannu J., Mori Y., Takagawa S., Chen G., et al. Fibroblast expression of the coactivator p.300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005, 52:1248-1258.
96. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
97. Postlethwaite A.E., Holness M.A., Katai H., Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992, 90:1479-1485.
98. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Choi J., Xiao H.Q., et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003, 48:2262-2274.
99. Parel Y., Aurrand-Lions M., Scheja A., Dayer J.M., Roosnek E., Chizzolini C. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007, 56:3459-3467.
100. Leask A., Abraham D. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006, 119:4803-4810.
101. Chizzolini C., Raschi E., Rezzonico R., Testoni C., Mallone R., Gabrielli A., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602-1613.
102. Fineschi S., Goffin L., Rezzonico R., Cozzi F., Dayer J.M., Meroni P.L., et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008, 58:3913-3923.
103. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., Lauwerys B.R., Wikström G., et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009, 60:1137-1144.
104. Barst R.J. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005, 115:2691-2694.
105. Ghofrani H.A., Seeger W., Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353:1412-1413.
106. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005, 171:1279-1285.
107. Sabnani I., Zucker M.J., Rosenstein E.D., Baran D.A., Arroyo L.H., Tsang P., et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009, 48:49-52.
108. Spiera R.F., Gordon J.K., Mersten J.N., Magro C.M., Mehta M., Wildman H.F., et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011, 70:1003-1009.
109. Mouthon L. SSc in 2011: from mechanisms to medicines. Nat Rev Rheumatol 2012, 8:72-74.
110. Bagnato G., Bitto A., Pizzino G., Irrera N., Sangari D., Cinquegrani M., et al. Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis. Rheumatology (Oxford) 2013, 52:1377-1386.
111. Maurer B., Distler J.H.W., Distler O. The Fra-2 transgenic mouse model of systemic sclerosis. Vascul Pharmacol 2013, 58:194-201.
112. Tyndall A., Fistarol S. The differential diagnosis of systemic sclerosis. Curr Opin Rheumatol 2013, 25:692-699.
113. Arnett F.C. Is scleroderma an autoantibody mediated disease?. Curr Opin Rheumatol 2006, 18:579-581.
114. Sato S., Fujimoto M., Hasegawa M., Takehara K., Tedder T.F. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41:1123-1133.
115. Matsushita T., Sato S. [The role of BAFF in autoimmune diseases]. Nihon Rinsho Meneki Gakkai Kaishi 2005, 28:333-342.
116. Bosello S., Pers J.O., Rochas C., Devauchelle V., De Santis M., Daridon C., et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007, 20:1-8.
117. Kraaij M.D., van Laar J.M. The role of B cells in systemic sclerosis. Biologics 2008, 2:389-395.
118. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146.
119. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.D., Uchida J., Fujimoto M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
120. Sunderkötter C., Riemekasten G. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology (Oxford) 2006, 45:iii33-iii35.
121. Chizzolini C., cells T. B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008, 20:707-712.
122. Ong C., Wong C., Roberts C.R., Teh H.S., Jirik F.R. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998, 28:2619-2629.
123. Isaacs J.D., Hazleman B.L., Chakravarty K., Grant J.W., Hale G., Waldmann H. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 1996, 23:1103-1106.
124. Stratton R.J., Wilson H., Black C.M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001, 40:84-88.
125. Van Bon L., Affandi A.J., Broen J., Christmann R.B., Marijnissen R.J., Stawski L., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370:433-443.